Mutated BRAF and personalised medicine in differentiated thyroid cancer
Mené sur 51 patients atteints d'un cancer papillaire de la thyroïde de stade récidivant ou métastatique présentant la mutation V600E du gène BRAF et réfractaire à l'iode radioactif, cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse globale, et la toxicité du vémurafénib
In The Lancet Oncology, Marcia Brose and colleagues report findings of a phase 2 study of vemurafenib that reflects the emerging era of personalised medicine in differentiated thyroid cancer. Building on previous successes in melanoma, patients with BRAF mutation-positive differentiated thyroid cancer refractory to radioactive iodine were enrolled into the current study and treated with the BRAF inhibitor vemurafenib to assess whether they might benefit similarly to patients with BRAF mutation-positive melanoma.
The Lancet Oncology , commentaire, 2015